Joint Formulary & PAD

Finerenone - Chronic kidney disease in type 2 diabetes

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Finerenone
Indication :
Chronic kidney disease in type 2 diabetes
Group Name :
Keywords :
TA877, stage 3, stage 4, CKD, albuminuria
Brand Names Include :
Kerendia
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Finerenone is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic kidney disease in type 2 diabetes.

  • No records returned.

Committee Recommendations (1)

The Surrey Heartland Integrated Care System Area Prescribing Committee agree that finerenone should be a treatment option as recommended line with NICE TA877 Finerenone for treating chronic kidney disease in type 2 diabetes. 


Finerenone for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians). 


Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient's medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication